This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
This activity is presented by recognized experts in the area of SLE and is designed to improve clinical competence and physician behavior as related to providing care for patients with this disease. Common clinical presentations will be portrayed to demonstrate effective use of screening and diagnostic tools, including manifestation of lupus nephritis. Current evidence-based treatment recommendations and emerging novel treatments, as well as monitoring for side effects of antirheumatic disease medications and addressing healthcare maintenance in patients with SLE, will also be discussed. A highly interactive case simulation will be interspersed with faculty commentary on the learners’ decision-making process to help learners connect new knowledge to its application in practice. Educational strategies to facilitate competency-based self-assessment, reflection on practice, and practice improvement will be used to optimize the educational experience and outcomes.
This educational activity is designed for rheumatologists. Other specialists and rheumatology allied health professionals whose scope of practice includes caring for patients with SLE may also benefit from participation in this activity.
Upon completion of this activity, learners will be better able to:
Review the screening and testing to diagnose SLE and specific organ dysfunction
Discuss the utilization of hydroxychloroquine in patients with SLE
Define the evidence-based therapies for treating lupus nephritis
Describe novel treatments for SLE
Emphasize the importance of screening and treatment for cardiovascular disease risk factors in patients with SLE
Conflict Of Interest Disclosure Policy
Educational activities sponsored by CME Enterprise must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Faculty disclosures are reported under the Faculty subheading below.
Chairperson Karen E. Hansen, MD, MS Associate Professor of Medicine Division of Rheumatology University of Wisconsin School of Medicine and Public Health Madison, WI
Dr. Hansen serves as a consultant for Deltanoid Pharmaceuticals.
Alan J. Bridges, MD Professor of Medicine, Division of Rheumatology University of Wisconsin School of Medicine and Public Health Chief of Staff William S. Middleton Memorial Veterans Hospital Madison, WI
Dr. Bridges has no relevant relationships to disclose in regard to this activity.
Alvin F. Wells, MD, PhD Director Rheumatology and Immunotherapy Center Franklin, WI
Dr. Wells serves on the Speakers Bureau for GlaxoSmithKline and has done contracted research for Lilly.
Independent Physician Reviewer Maria Dall'Era, MD Associate Professor of Medicine Director, Lupus Clinic and Rheumatology Clinical Research Center University of California San Francisco, CA
Dr. Dall’Era has no relevant relationships to disclose in regard to this activity.
Click here for a PDF of complete faculty biographies.
Marianna Shershneva, MD, PhD, and Stephanie Poehner have no relevant relationships to disclose in regard to this activity.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). CME Enterprise is accredited by the ACCME to provide continuing medical education for physicians.
CME Enterprise designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
The audience is advised that no presentations in this continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of CME Enterprise or the commercial supporter.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
Click "Let's Begin" to start the case. Throughout the case simulation, please click on the various learner prompts (eg, continue, proceed to the next question, etc) at the bottom of the screen.
This case simulation, integrated with video and audio presentations, is estimated to take 60 minutes to complete. You may leave the case and sign in at a later time to pick up where you left off.
After you have completed the simulation, you will be directed to complete the post-test and provide evaluation feedback; you will then be instructed on how to claim CME credit.
Learners should be able to play this case video in any browser. In order to ensure the best experience, we recommend the following browsers, with all current updates applied:
Internet Explorer (PC) Versions 10, 11
Safari (PC) Versions 6, 7
Safari (iOS) iOS 6, 7
Firefox (PC) Versions 24, 25
Chrome (PC) Version 36
Chrome (iOS) Version 31
Chrome (Android) Version 30
CME Enterprise retains records only in accordance with ACCME requirements. We will not share your information with any other organizations.